Elicio Therapeutics, Inc. SEC filings ELTX

Elicio Therapeutics, Inc. has 384 filings in SEC EDGAR's recent list, going back to Mar 4, 2014. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
10-K/A Amended annual report Apr 29, 2026 Dec 31, 2025
10-K Annual report Mar 12, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 9, 2025 Dec 31, 2024
10-K Annual report Mar 31, 2025 Dec 31, 2024
ARS Annual report to shareholders Sep 27, 2024 Dec 31, 2023
10-K/A Amended annual report Apr 29, 2024 Dec 31, 2023
10-K Annual report Mar 29, 2024 Dec 31, 2023
10-K/A Amended annual report Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 17, 2023 Dec 31, 2022
10-K Annual report Mar 30, 2022 Dec 31, 2021
10-K Annual report Mar 30, 2021 Dec 31, 2020

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ELTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1601485
Former names
Angion Biomedica Corp. (until May 30, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.